1. Home

Menu

Products
Patient Care
AlphaLiquidⓇ100

AlphaLiquidⓇ100 is a liquid biopsy test designed for patients with advanced solid cancers. Our patented UniqSeqⓇ technology detects minuscule amount of ctDNA (circulating tumor DNA) in the bloodstream for comprehensive genomic analysis.

AlphaLiquidⓇ100 detects the four classes of variations (SNV, INDEL, fusion, and CNV) and the two genomic signatures of immunotherapy (MSI and TMB) in 118 NCCN-recommended genes associated with major cancer types. With this data, IMB Dx can provide information on appropriate therapy options and related on-going clinical trials.

Recommended for：

  • Patients who are unable to go through invasive tissue biopsy.
  • Patients whose tumor tissue cannot be obtained.
  • Patients who have not been tested for a long time, or whose tissue biopsy result is outdated.
  • Patients with more than one key mutations detected from recent biopsy.
  • Patients who need more than a single gene test for appropriate diagnosis and therapy.

Workflow

Ordering

Sample Collection

Transportation

Analysis Report

Icon reference: Arrow icons created by Creative Stall Premium - Flaticon

118 Gene List

SNVs & InDels(117) CNVs(27) Fusions(10)
ABL1 AKT1 AKT2 ALK APC AR ARAF AKT1 FGFR2 ALK
ARID1A ATM BARD1 BRAF BRCA1 BRCA2 BRIP1 AR FGFR3 BCR
BTK CBL CCND1 CCND2 CCNE1 CD274 CDH1 BRAF KDR BRAF
CDK12 CDK4 CDK6 CDKN2A CEBPA CHEK1 CHEK2 BRCA1 KIT EGFR
CSF1R CTNNB1 DDR2 DPYD EGFR ERBB2 ERBB3 CCND1 KRAS FGFR2
ESR1 FANCL FBXW7 FGFR1 FGFR2 FGFR3 FLT3 CCND2 MAPK1 FGFR3
GATA3 GNA11 GNAQ GNAS HRAS IDH1 IDH2 CCNE1 MDM2 NTKR1
IGF1R JAK2 JAK3 KDM6A KDR KEAP1 KIT CD274 MET NTRK2
KRAS MAP2K1 MAP2K2 MAPK1 MAPK3 MDM2 MET CDK12 MYC RET
MLH1 MPL MSH2 MSH6 MTOR MYC MYCN CDK4 MYCN ROS1
NF1 NF2 NFE2L2 NOTCH1 NPM1 NRAS NTRK1 CDK6 PDGFRA  
NTRK2 NTRK3 PALB2 PDCDILG2 PDGFRA PDGFRB PIK3CA EGFR PIK3CA  
PIK3R1 PMS2 PPP2R1A PPP2R2A PTEN PTPN11 RAD51B ERBB2 RAF1  
RAD51C RAD51D RAD54L RAF1 RB1 RET RHEB FGFR1    
RHOA RIT1 RNF432 ROS1 RUNX1 SETD2 SMAD4      
SMO STAG2 STK11 TCF7L2 TERT TOP2A TP53      
TSC1 TSC2 U2AF1 VHL UGT1A1          

Concordance with Tissue Data

Analyzed based on data from：
  • Patients subject to the 10K Project.
  • Patients before first-line therapy for lung, colorectal, and breast cancer.
  • Patients participating in clinical trials carried out by the KFDA.
  • Patients participating in clinical trials carried out by major hospitals in Seoul.
 90-100%
concordance

Recommended for patients before anticancer therapy or with cancer in progress.


  • TEL: +886-2-2655-8525
  • FAX: +886-2-2655-8526
  • Address：3F-1, No.3-1, Park Street, Nangang District, Taipei City, Taiwan (R.O.C)